Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Braveheart Bio shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Braveheart Bio's shares outstanding was 52M at Sep 30, 2026.
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 52M | – |
| Q2 FY2026 | Jun 30, 2026 | 7M | – |
| Q3 FY2025 | Sep 30, 2025 | 6M | – |
| Q2 FY2025 | Jun 30, 2025 | 3M | – |
See a number that looks wrong?